0001104659-19-035014.txt : 20190717 0001104659-19-035014.hdr.sgml : 20190717 20190612142259 ACCESSION NUMBER: 0001104659-19-035014 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ContraVir Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 CORRESP 1 filename1.htm

 

ContraVir Pharmaceuticals, Inc.

399 Thornall Street

Edison, NJ 08837

 

June 12, 2019

 

VIA EDGAR

United States Securities

and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Dorrie Yale

 

Re:                             ContraVir Pharmaceuticals, Inc.

Form S-1, as amended

File No. 333-231604

 

Dear Ms. Yale:

 

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), ContraVir Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Standard Time, on Thursday, June 13, 2019, or as soon thereafter as possible.

 

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

 

 

Thank you,

 

 

 

CONTRAVIR PHARMACEUTICALS, INC.

 

 

 

By:

/s/ Robert Foster

 

Name:

Robert Foster

 

Title:

Chief Executive Officer